· Dr. Juby Jacob-Nara brings
a wealth of medical and clinical development knowledge and extensive expertise
across multiple therapeutic areas and will lead medical strategy at Celltrion
USA
JERSEY CITY, N.J., June 2, 2025 – Celltrion USA today
announced the appointment of Dr. Juby Jacob-Nara, M.D. as Senior Vice President
and Chief Medical Officer. This key leadership appointment reinforces Celltrion’s
unwavering patient focus and commitment to expanding access to innovative
biologics to improve care for U.S. patients.
“We are delighted to
welcome Dr. Jacob-Nara to the Celltrion team,” said Mr. Bon Joong Kim, CEO at
Celltrion USA. “Dr. Jacob-Nara’s deep clinical expertise, combined with strong
industry experience, will be instrumental to our team and customers as we continue
to accelerate the delivery of life-changing therapies to patients and expand
our presence in the U.S. market.”
As a dedicated public
health physician, Dr. Jacob-Nara brings more than 25 years of experience across
sales, marketing, U.S. and global medical affairs, and clinical development
across general, specialty, and precision medicines - including biologics,
vaccines, and over-the-counter products. Driven by a strong commitment to
patient value, she has contributed to the development and expanded access of
specialty pharmaceuticals, vaccines, biologics, and direct-to-consumer
medicines, with a focus on respiratory, autoimmune, infectious diseases, pain
management, and women’s health. She has successfully contributed to more than
50 product launches, including vaccines in the U.S. and globally.
“I am excited to join
Celltrion at such a critical and promising time in its growth and evolution,”
said Dr. Jacob-Nara. “I look forward to being part of the team, driving
transformational change in the pharmaceutical industry and contributing to our
shared mission of harnessing scientific innovation to improve outcomes for
patients and healthcare professionals across the country.”
Prior to joining
Celltrion USA, Dr. Jacob-Nara has held leadership roles at pharmaceutical
companies including Merck, Novartis, GSK, AstraZeneca, Pfizer. Most recently
serving as Vice President and Head of Global Medical Affairs for Pulmonology,
Rhinology & Allergy, Gastroenterology at Sanofi.
Dr. Jacob-Nara holds a Bachelor
of Medicine, Bachelor of Surgery (MBBS) from Kasturba Medical College, a Master
of Public Health (MPH) from Columbia University, and a Doctor of Health Science
(DHSc) from Radford University. She also earned dual MBAs from Cornell University
and Queen’s University.
###
Notes to Editors:
About Celltrion USA
Celltrion
USA is Celltrion's U.S. subsidiary established in 2018. Headquartered in New
Jersey, Celltrion USA is committed to expanding access to innovative biologics
to improve care for U.S. patients. Celltrion USA will continue to leverage
Celltrion's unique heritage in biotechnology, supply chain excellence and
best-in-class sales capabilities to improve access to high-quality
biopharmaceuticals for U.S. patients. For more information, please visit www.celltrionusa.com and stay updated with our latest
news and events on our social media: LinkedIn.
About Celltrion, Inc.
Celltrion
is a leading biopharmaceutical company that specializes in researching,
developing, manufacturing, marketing and sales of innovative therapeutics that
improve people's lives worldwide. Celltrion
is a pioneer in the biosimilar space, having launched the world's first
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a
range of therapeutic areas including immunology, oncology, hematology,
ophthalmology and endocrinology. Beyond biosimilar products, we are committed
to advancing our pipeline with novel drugs to push the boundaries of scientific
innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us. and stay
updated with our latest news and events on our social media: LinkedIn, Instagram, X, and Facebook.
Certain
information set forth in this press release contains statements related to our
future business and financial performance and future events or developments
involving Celltrion, Inc.
and its subsidiaries that may constitute forward-looking statements under
pertinent securities laws. This press release contains forward looking
statements. These
statements may be also identified
by words such as “prepares”,
“hopes to”,
“upcoming”,
”plans to”,
“aims to”, “to
be launched”, “is
preparing”,
“once gained”, “could”, “with the aim of”, “may”,
“once identified”,
“will”, “working
towards”, “is
due”, “become
available”, “has
potential to”, “anticipate” the negative of these words or such other variations thereon or
comparable terminology.
In addition, our
representatives may make oral forward-looking statements. Such statements are
based on the current expectations and certain assumptions of Celltrion, Inc. and its subsidiaries' management, of which
many are beyond its control.
Forward-looking
statements are provided to allow potential investors the opportunity to
understand management’s beliefs and opinions in respect of the future so that
they may use such beliefs and opinions as one factor in evaluating an
investment. These statements are not guarantees of future performance and undue
reliance should not be placed on them.
Such
forward-looking statements necessarily involve known and unknown risks and
uncertainties associated with the company's business, including the risk
factors disclosed in its Annual Report and/or Quarterly Reports, which may
cause actual performance and financial results in future periods to differ
materially from any projections of future performance or results expressed or
implied by such statements.
Celltrion, Inc. and its subsidiaries undertake no obligation
to update forward-looking statements if circumstances or management’s estimates
or opinions should change except as required by applicable securities laws.
US-25-00059 June 2025